N'guessan Benoit Banga, Twumasi-Ankrah Jessica Sarpongmaa, Amponsah Seth Kwabena, Adams Ismaila, Poakwah Albert Kyei-Kankam, Brown Charles, Adinortey Michael Buenor, Sarkodie Joseph Adusei, Adi-Dako Ofosua, Asiedu-Gyekye Isaac Julius, Appiah-Opong Regina
Department of Pharmacology and Toxicology, School of Pharmacy, College of Health Sciences, University of Ghana, PO Box LG 43 Legon, Accra, Ghana.
Department of Pharmacology and Toxicology, School of Pharmacy, College of Health Sciences, University of Ghana, PO Box LG 43 Legon, Accra, Ghana.
Biomed Pharmacother. 2022 May;149:112892. doi: 10.1016/j.biopha.2022.112892. Epub 2022 Mar 28.
Obesity and overweight are metabolic disorders associated with oxidative stress, and risk factors for many chronic diseases. We sought to investigate the effects of Metaswitch dietary supplement on weight gain and associated acute metabolic alterations in a high-fat diet-induced overweight rat model.
Female Sprague Dawley (SD) rats were put into 6 groups. Control groups were fed normal (NCD) or high-fat diet (HFD). Treatment groups on HFD receieved 3 different daily doses of Metaswitch for 3 weeks. Another group on HFD received Slimrite® (phenylpropanolamine), a standard drug. Rats on HFD also received cyproheptadine to stimulate appetite. Food consumption and anthropometric parameters were determined weekly. Serum lipids, glucose level, hepatic lipid peroxidation, and antioxidant activity were used to assess overweight in rats.
Food intake remained relatively constant among groups. Rats on HFD had significantly increased body weight compared to rats fed NCD. Metaswitch significantly prevented weight gain; this effect was greater or similar to rats administered Slimrite, but was not dose-dependant. No significant changes occurred in the levels of serum lipids and glucose among the groups. However, serum triglyceride (TG) was significantly increased. The TG/HDL-C ratio revealed significant metabolic alterations which was prevented by Metaswitch. Catalase activity was significantly decreased in the HFD untreated group but was restored in Metaswitch-treated groups.
A 3-week HFD regimen with cyproheptadine supplementation in female SD rats resulted in a significant increase in body weight and acute metabolic alterations. The aforementioned changes were found to have been prevented with the administration of Metaswitch.
肥胖和超重是与氧化应激相关的代谢紊乱，也是许多慢性疾病的危险因素。我们试图研究Metaswitch膳食补充剂对高脂饮食诱导的超重大鼠模型体重增加及相关急性代谢改变的影响。
将雌性斯普拉格-道利（SD）大鼠分为6组。对照组分别给予正常饮食（NCD）或高脂饮食（HFD）。高脂饮食组的治疗组连续3周每天接受3种不同剂量的Metaswitch。另一高脂饮食组接受标准药物Slimrite®（苯丙醇胺）。高脂饮食组的大鼠还接受赛庚啶以刺激食欲。每周测定食物摄入量和人体测量参数。用血清脂质、血糖水平、肝脏脂质过氧化和抗氧化活性来评估大鼠的超重情况。
各组间食物摄入量保持相对稳定。与喂食正常饮食的大鼠相比，高脂饮食组的大鼠体重显著增加。Metaswitch显著阻止了体重增加；这种作用与给予Slimrite的大鼠相似或更强，但不依赖剂量。各组间血清脂质和血糖水平无显著变化。然而，血清甘油三酯（TG）显著升高。TG/HDL-C比值显示出显著的代谢改变，而Metaswitch可预防这种改变。未处理的高脂饮食组过氧化氢酶活性显著降低，但在Metaswitch处理组中恢复。
在雌性SD大鼠中，为期3周的高脂饮食方案加用赛庚啶导致体重显著增加和急性代谢改变。发现给予Metaswitch可预防上述变化。
